FDA Approves Biogen’s Drug for Postpartum Depression
- Posted by ISPE Boston
- On August 10, 2023
Biogen and its collaboration partner Sage Therapeutics have announced that the FDA has approved Zurzuvae (zuranolone) for adults with postpartum depression (PPD). Zurzuvae is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. Zurzuvae is expected to launch and be commercially available in the […]
Read More